These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19746253)

  • 61. Treatment of methadone-induced torsades de pointes with lidocaine.
    Rajpal S; Mundi AS; Reddy PC; Akkus NI
    J La State Med Soc; 2013; 165(6):338-41. PubMed ID: 25073261
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
    Singh BN; Wadhani N
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Does subclinical hypothyroidism explain the increased susceptibility of women to torsades de pointes?
    Lehmann MH; Frankovich D; Baga JJ; Pires LA; Schuger CD; Steinman RT; Rabinowe SL
    Am J Cardiol; 1997 Apr; 79(7):963-5. PubMed ID: 9104914
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Torsade de pointes during anti-arrhythmia treatment with amiodarone].
    Schlienger RG; Haefeli WE; Lüscher TF
    Schweiz Rundsch Med Prax; 1993 Feb; 82(6):173-5. PubMed ID: 7679520
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.
    Naksuk N; Sugrue AM; Padmanabhan D; Kella D; DeSimone CV; Kapa S; Asirvatham SJ; Lee HC; Ackerman MJ; Noseworthy PA
    J Interv Card Electrophysiol; 2019 Mar; 54(2):189-196. PubMed ID: 30353374
    [TBL] [Abstract][Full Text] [Related]  

  • 66. QT Interval prolongation and torsades de pointes due to a coadministration of ciprofloxacin and azimilide in a patient with implantable cardioverter-defibrillator.
    Kaźmierczak J; Peregud-Pogorzelska M; Rzeuski R
    Pacing Clin Electrophysiol; 2007 Aug; 30(8):1043-6. PubMed ID: 17669094
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Clue Is in the U Wave: Torsades de Pointes Ventricular Tachycardia in a Hypokalemic Woman on Methadone.
    Fitzpatrick JK; Goldschlager N
    Ann Emerg Med; 2018 Apr; 71(4):473-476. PubMed ID: 29566890
    [No Abstract]   [Full Text] [Related]  

  • 69. Short-coupled variant of torsade de pointes.
    Ruan Y; Wang L
    J Tongji Med Univ; 2001; 21(1):30-1. PubMed ID: 11523241
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Torsades de pointes ventricular tachycardia caused by terodiline (Mictrol)?].
    Pedersen JL; Ohmsen E
    Ugeskr Laeger; 1992 Sep; 154(40):2760-1. PubMed ID: 1413214
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Drug-induced torsades de pointes and implications for drug development.
    Fenichel RR; Malik M; Antzelevitch C; Sanguinetti M; Roden DM; Priori SG; Ruskin JN; Lipicky RJ; Cantilena LR;
    J Cardiovasc Electrophysiol; 2004 Apr; 15(4):475-95. PubMed ID: 15090000
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The use of isoproterenol and phenytoin to reverse torsade de pointes.
    Omar HR; Sprenker C; Karlnoski R; Mangar D; Camporesi EM
    Am J Emerg Med; 2014 Jun; 32(6):683.e5-7. PubMed ID: 24462399
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Drug-induced torsade de pointes. Incidence, management and prevention.
    Faber TS; Zehender M; Just H
    Drug Saf; 1994 Dec; 11(6):463-76. PubMed ID: 7727055
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Two cases of torsades de pointes caused by sotalol therapy.
    Cammu G; Geelen P; Baetens P; De Vos J; Demeyer I
    Resuscitation; 1999 Jan; 40(1):49-51. PubMed ID: 10321848
    [No Abstract]   [Full Text] [Related]  

  • 75. Nicorandil, a potassium channel opener, abolished torsades de pointes in a patient with complete atrioventricular block.
    Watanabe O; Okumura T; Takeda H; Nakamura W; Segawa K; Ito H; Yoshimoto N
    Pacing Clin Electrophysiol; 1999 Apr; 22(4 Pt 1):686-8. PubMed ID: 10234727
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Torsade de pointes induced by ajmaline.
    Haverkamp W; Mönnig G; Kirchhof P; Eckardt L; Borggrefe M; Breithardt G
    Z Kardiol; 2001 Aug; 90(8):586-90. PubMed ID: 11565214
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dofetilide-induced long QT and torsades de pointes.
    Aktas MK; Shah AH; Akiyama T
    Ann Noninvasive Electrocardiol; 2007 Jul; 12(3):197-202. PubMed ID: 17617063
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
    Amankwa K; Krishnan SC; Tisdale JE
    Clin Pharmacol Ther; 2004 Mar; 75(3):242-7. PubMed ID: 15001976
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Torsades de pointes with Almokalant, a new class III antiarrhythmic drug.
    Wiesfeld AC; Crijns HJ; Bergstrand RH; Almgren O; Hillege HL; Lie KI
    Am Heart J; 1993 Oct; 126(4):1008-11. PubMed ID: 8213422
    [No Abstract]   [Full Text] [Related]  

  • 80. The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review.
    Hunt N; Stern TA
    Psychosomatics; 1995; 36(6):541-9. PubMed ID: 7501784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.